Platelet Inhibition with Cangrelor

To the Editor: Harrington et al. 1 and Bhatt et al. 2 (Dec. 10 issue) describe the results of studies of platelet inhibition with intravenous cangrelor in patients undergoing percutaneous coronary intervention (PCI). In the study by Harrington et al., 996 patients with myocardial infarction with ST-segment elevation were enrolled. In this select group of patients, the administration of oral antiplatelet agents is not always an option. In our institution, such drugs could not be administered to 2% of patients presenting with ST-segment–elevation myocardial infarction who underwent primary PCI. Such patients include those who have undergone intubation after cardiac arrest or who . . .